Table 2.
Characteristics of the studies included in the meta-analysis.
| Study (Year) | Country | Number of Patients | PCOS Patients’ Age | |
|---|---|---|---|---|
| PCOS | Control | |||
| Altuntaş (2022) [6] | Turkey | 167 | 73 | 25.87 ± 5.64 |
| Karsten (2021) [7] | Netherlands | 73 | 100 | 34.1 ± 4.1 |
| Deeks (2010) [15] | Australia | 48 | - | 32.5 ± 7.98 |
| Dybciak (2022) [16] | Poland | 230 | 199 | 20–40 |
| Sheikh (2021) [17] | United Kingdom | 502 | - | - |
| Radhakrishnan (2018) [19] | India | 100 | - | 16–36 |
| Tariq (2021) [20] | Pakistan | 135 | 135 | 15–45 |
| Kogure (2019) [33] | Brazil | 120 | - | 28.8 ± 5.2 |
| Bazarganipour (2013) [34] | Iran | 300 | - | 26.56 ± 4.44 |
| Batool (2016) [35] | Pakistan | 137 | 137 | 25.0 ± 8.6 |
| Barry (2011) [37] | United Kingdom | 76 | 49 | 28.8 ± 4.81 |
| Saxena (2022) [42] | India | 70 | - | 25.7 ± 7.6 |
| Alur-Gupta (2021) [43] | United States of America | 272 | - | Median 28.9 |
| Light (2020) [44] | United Kingdom | 487 | - | 30.81 ± 7.65 |
| Cirik (2016) [45] | Turkey | 101 | 49 | 24.44 ± 4.23 |
| Benson (2010) [46] | Germany | 448 | - | 29.6 ± 5.5 |
| Sukhapure (2022) [47] | New Zealand | 33 | 41 | 29.24 ± 6.81 |
| Fatemeh (2021) [48] | Iran | 239 | - | 30.92 ± 5.49 |
| Dag (2019) [49] | Turkey | 53 | 38 | 22.69 ± 4.54 |